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Background
Plants constitute promising systems for the alternative
production of valuable recombinant proteins. Recently,
ELELYSO™, an enzymatic drug developed by the Israeli
company Protalix Biotherapeutics to treat Type 1 Gau-
cher’s disease, became the first plant-derived therapeutic
product to reach marketable status [1]. This confirms the
inherent potential of plant systems for the large-scale
production of pharmaceuticals and industrial proteins
with high quality and at competitive costs. Soybeans
[Glycine max (L.) Merrill] provide a potential economic-
ally viable platform for the large-scale production of dif-
ferent therapeutic molecules. Plant seeds are specialized
in the stable accumulation of proteins at high levels,
representing an excellent source of abundant and cheap
biomass. Additionally, the vegetative growth of plants
can be significantly extended under a daily photoperiod
of 23 h of light, inducing more than a tenfold increase in
seed production when compared with plants cultivated
under field conditions [2]. In this report we present the
recombinant biosynthesis and the molecular and func-
tional characterization of two important therapeutic pro-
teins in transgenic soybean seeds: the 22 kDa human
growth hormone (hGH) and the 56 kDa human coagula-
tion factor IX (hFIX), a vitamin K-dependent serine-pro-
tease glycoprotein utilized to treat Type B Christmas
disease, the second most frequent haemophilia variant
[3,4].
Methods
A biolistic process was used to introduce the plasmids
pbcong3hGH (4,786 bp) and pbcong3FIX (5,406 bp),
respectively carrying the hgh and hFIX coding sequences
under the transcriptional control of the alpha prime (a’)
subunit of b-conglycinin tissue-specific promoter from
Glycine max (L.) Merrill and the a-Coixin signal peptide
from Coix lacryma-jobi, in soybean embryonic axes
from mature seeds (cv. BR-16). Independent transgenic
lines were analyzed by PCR and characterized by South-
ern blot. The transcription levels of the correspondent
coding sequences were evaluated by RT-PCR of imma-
ture seeds and the accumulation of the proteins in the
protein storage vacuoles (PSVs) of the seeds was
detected by Western Blot and ultrastructural immunocy-
tochemistry assays. Partial N-terminal sequencing of
both proteins was determined by nano-Lc mass spectro-
metry assay. The biological activities of the molecules
were evaluated by somatogenic activity bioassay (for the
hGH), and by activated partial thromboplastin time
assay (for the hFIX).
Results
Expression levels of bioactive hGH and hFIX were,
respectively, of up to 2.9% of total soluble seed protein
content (corresponding to approximately 9 g kg-1) and
up to 0.23% (0.8 g Kg-1). Immunocytochemistry assays
indicated that both molecules were efficiently directed
to protein storage vacuoles in seed cotyledonary cell.
The recombinant hGH and hFIX protein sequences
were confirmed by mass spectrometry characterization
and showed no post-translational modifications on the
spectra covered by the assays. The somatogenic activity
bioassay demonstrated that the hGH expressed in soy-
bean seeds is fully active. Protein extracts from transgenic
seeds containing the hFIX showed a blood-clotting activ-
ity of up to 1.4% of normal plasma.
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Conclusionsand perspectives
Soybean seeds seem to be promising vehicles for the stable
accumulation of the recombinant hGH and hFIX, once it
was possible to detect biologically active molecules in
grains stored up to six years at room temperature.
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